IceCure Medical Ltd. announced the growing commercial adoption of their ProSense™ cryoablation system for breast cancer in Brazil, boosted by FDA authorization. The system, now approved in Brazil, is currently being used in various cancer treatments across the country.
Company Information
Company
IceCure Medical
Location
7 HaEshel Street
Caesarea, Haifa District, Israel
About
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Fundz sees it the moment IceCure Medical ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CaesareaManufacturingBiotechnologyHealth CareMedicalMedical Devicemedical devices